Metasztatikus kasztrációrezisztens prosztatadaganat korszerû kezelése

Translated title of the contribution: The modern treatment of metastatic castration-resistant prostate cancer

Zsófia Küronya, Krisztina Biró, Anikó Maráz, L. Géczi

Research output: Contribution to journalArticle

Abstract

The basic therapy of metastatic prostate carcinoma is androgen deprivation therapy. Unfortunately, almost all patients develop resistance to treatment that leads to castration-resistant prostate cancer. From 2010, 6 new active substances were registered for the treatment of metastatic castration-resistant prostate cancer, which dramatically improved the overall survival of patients. Two of these are treatments for the androgenic axis, the other drugs or therapeutic methods are immunotherapy, chemotherapy, isotope treatment and RANK-ligand inhibition. The year 2018 was a major success in the treatment of nonmetastatic castration-resistant prostate carcinoma, with the FDA authorizing both apalutamide and enzalutamide at this stage. The aim of this review is to present the standard of care of metastatic castration-resistant prostate cancer by disease stage, and to introduce the emerging treatment modalities presently assessed in clinical trials and discuss the open questions.

Original languageHungarian
Pages (from-to)41-50
Number of pages10
JournalMagyar onkologia
Volume63
Issue number1
Publication statusPublished - Mar 19 2019

Fingerprint

Castration
Prostatic Neoplasms
Therapeutics
Prostate
RANK Ligand
Carcinoma
Standard of Care
Isotopes
Immunotherapy
Androgens
Clinical Trials
Drug Therapy
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Metasztatikus kasztrációrezisztens prosztatadaganat korszerû kezelése. / Küronya, Zsófia; Biró, Krisztina; Maráz, Anikó; Géczi, L.

In: Magyar onkologia, Vol. 63, No. 1, 19.03.2019, p. 41-50.

Research output: Contribution to journalArticle

Küronya, Z, Biró, K, Maráz, A & Géczi, L 2019, 'Metasztatikus kasztrációrezisztens prosztatadaganat korszerû kezelése', Magyar onkologia, vol. 63, no. 1, pp. 41-50.
Küronya, Zsófia ; Biró, Krisztina ; Maráz, Anikó ; Géczi, L. / Metasztatikus kasztrációrezisztens prosztatadaganat korszerû kezelése. In: Magyar onkologia. 2019 ; Vol. 63, No. 1. pp. 41-50.
@article{c7f62425d4294d00a8df2ee42e535e1b,
title = "Metasztatikus kasztr{\'a}ci{\'o}rezisztens prosztatadaganat korszer{\^u} kezel{\'e}se",
abstract = "The basic therapy of metastatic prostate carcinoma is androgen deprivation therapy. Unfortunately, almost all patients develop resistance to treatment that leads to castration-resistant prostate cancer. From 2010, 6 new active substances were registered for the treatment of metastatic castration-resistant prostate cancer, which dramatically improved the overall survival of patients. Two of these are treatments for the androgenic axis, the other drugs or therapeutic methods are immunotherapy, chemotherapy, isotope treatment and RANK-ligand inhibition. The year 2018 was a major success in the treatment of nonmetastatic castration-resistant prostate carcinoma, with the FDA authorizing both apalutamide and enzalutamide at this stage. The aim of this review is to present the standard of care of metastatic castration-resistant prostate cancer by disease stage, and to introduce the emerging treatment modalities presently assessed in clinical trials and discuss the open questions.",
author = "Zs{\'o}fia K{\"u}ronya and Krisztina Bir{\'o} and Anik{\'o} Mar{\'a}z and L. G{\'e}czi",
year = "2019",
month = "3",
day = "19",
language = "Hungarian",
volume = "63",
pages = "41--50",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Metasztatikus kasztrációrezisztens prosztatadaganat korszerû kezelése

AU - Küronya, Zsófia

AU - Biró, Krisztina

AU - Maráz, Anikó

AU - Géczi, L.

PY - 2019/3/19

Y1 - 2019/3/19

N2 - The basic therapy of metastatic prostate carcinoma is androgen deprivation therapy. Unfortunately, almost all patients develop resistance to treatment that leads to castration-resistant prostate cancer. From 2010, 6 new active substances were registered for the treatment of metastatic castration-resistant prostate cancer, which dramatically improved the overall survival of patients. Two of these are treatments for the androgenic axis, the other drugs or therapeutic methods are immunotherapy, chemotherapy, isotope treatment and RANK-ligand inhibition. The year 2018 was a major success in the treatment of nonmetastatic castration-resistant prostate carcinoma, with the FDA authorizing both apalutamide and enzalutamide at this stage. The aim of this review is to present the standard of care of metastatic castration-resistant prostate cancer by disease stage, and to introduce the emerging treatment modalities presently assessed in clinical trials and discuss the open questions.

AB - The basic therapy of metastatic prostate carcinoma is androgen deprivation therapy. Unfortunately, almost all patients develop resistance to treatment that leads to castration-resistant prostate cancer. From 2010, 6 new active substances were registered for the treatment of metastatic castration-resistant prostate cancer, which dramatically improved the overall survival of patients. Two of these are treatments for the androgenic axis, the other drugs or therapeutic methods are immunotherapy, chemotherapy, isotope treatment and RANK-ligand inhibition. The year 2018 was a major success in the treatment of nonmetastatic castration-resistant prostate carcinoma, with the FDA authorizing both apalutamide and enzalutamide at this stage. The aim of this review is to present the standard of care of metastatic castration-resistant prostate cancer by disease stage, and to introduce the emerging treatment modalities presently assessed in clinical trials and discuss the open questions.

UR - http://www.scopus.com/inward/record.url?scp=85063299953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063299953&partnerID=8YFLogxK

M3 - Article

C2 - 30889620

AN - SCOPUS:85063299953

VL - 63

SP - 41

EP - 50

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -